Fintel reports that on March 11, 2025, B of A Securities upgraded their outlook for PTC Therapeutics (NasdaqGS:PTCT) from Underperform to Neutral.

Analyst Price Forecast Suggests 20.93% Upside

As of March 5, 2025, the average one-year price target for PTC Therapeutics is $63.48/share. The forecasts range from a low of $41.41 to a high of $118.65. The average price target represents an increase of 20.93% from its latest reported closing price of $52.49 / share.

See our leaderboard of companies with the largest price target upside.

The projected annual revenue for PTC Therapeutics is 1,081MM, an increase of 33.99%. The projected annual non-GAAP EPS is -3.63.

What is the Fund Sentiment?

There are 512 funds or institutions reporting positions in PTC Therapeutics. This is an increase of 46 owner(s) or 9.87% in the last quarter. Average portfolio weight of all funds dedicated to PTCT is 0.16%, an increase of 6.96%. Total shares owned by institutions decreased in the last three months by 2.34% to 86,913K shares. The put/call ratio of PTCT is 0.78, indicating a bullish outlook.

What are Other Shareholders Doing?

Rtw Investments holds 7,393K shares representing 9.37% ownership of the company. No change in the last quarter.

Armistice Capital holds 6,378K shares representing 8.09% ownership of the company. In its prior filing, the firm reported owning 7,235K shares , representing a decrease of 13.44%. The firm decreased its portfolio allocation in PTCT by 8.50% over the last quarter.

Wellington Management Group Llp holds 4,787K shares representing 6.07% ownership of the company. In its prior filing, the firm reported owning 7,893K shares , representing a decrease of 64.88%. The firm decreased its portfolio allocation in PTCT by 89.20% over the last quarter.

VGHCX - Vanguard Health Care Fund Investor Shares holds 4,026K shares representing 5.10% ownership of the company. In its prior filing, the firm reported owning 4,169K shares , representing a decrease of 3.56%. The firm increased its portfolio allocation in PTCT by 21.67% over the last quarter.

Toronto Dominion Bank holds 3,287K shares representing 4.17% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.

PTC Therapeutics Background Information
(This description is provided by the company.)

PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines and its mission to provide access to best-in-class treatments for patients who have an unmet medical need. The Company's strategy is to leverage its strong scientific expertise and global commercial infrastructure to maximize value for its patients and other stakeholders.